0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Strides Pharma Gets Usfda Approval For Generic Ibuprofen Oral Suspension
News Feed
course image
  • 31 May 2022
  • Admin
  • News Article

Strides Pharma Gets Usfda Approval For Generic Ibuprofen Oral Suspension

The Product Is Bioequivalent And Therapeutically Equivalent To The Reference Listed Drug Motrin Oral Suspension, 100 Mg/5 Ml, Of Mcneil Consumer Healthcare (Mcneil), It Added. Strides Pharma Science Ltd (Strides) On Monday Said Its Singapore-Based Arm Has Received Approval From The Us Health Regulator For Generic Ibuprofen Oral Suspension, Which Is Used To Relieve Pain From Various Conditions. The Approval Granted To The Company'S Stepdown Wholly-Owned Subsidiary Strides Pharma Global Pte Ltd, Singapore, By The Us Food And Drug Administration (Usfda) Is For Ibuprofen Oral Suspension Of The Strength Of 100 Mg/5 Ml, The Company Said In A Statement. The Product Is Bioequivalent And Therapeutically Equivalent To The Reference Listed Drug Motrin Oral Suspension, 100 Mg/5 Ml, Of Mcneil Consumer Healthcare (Mcneil), It Added. The Product Will Be Manufactured At The Company'S Facility In Bengaluru And Will Be Marketed By Strides Pharma Inc In The Us Market. Citing Iqvia Mat March 2022 Data, The Company Said The Us Market For Ibuprofen Oral Suspension 100 Mg/5 Ml Is Approximately Usd 66 Million. Strides Said It Has A Total Of 274 Abbreviated New Drug Application (Anda) Filings With Usfda, Of Which 250 Andas Have Been Approved And 24 Are Pending Approval. It Currently Has Around 60 Commercialised Products In The Us And Has Set A Target To Launch Around 20 New Products Every Year From The Combined Portfolio, Strides Noted

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form